Project Details
Description
HDAC inhibitor sensitization of BRCA-1/2 mutant and wild-type high-grade serous ovarian cancer cells to PARP inhibitor treatment
| Status | Finished |
|---|---|
| Effective start/end date | 9/15/21 → 8/31/23 |
Funding
- MAYO CLINIC ROCHESTER
- NATIONAL INSTITUTES OF HEALTH (NIH)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.